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There remains uncertainty about the impact of menopausal hormone therapy (MHT) on
women’s health. A systematic, comprehensive assessment of the effects on multiple out-
comes is lacking. We conducted an umbrella review to comprehensively summarize evi-
dence on the benefits and harms of MHT across diverse health outcomes.
Methods and findings
We searched MEDLINE, EMBASE, and 10 other databases from inception to November
26, 2017, updated on December 17, 2020, to identify systematic reviews or meta-analyses
of randomized controlled trials (RCTs) and observational studies investigating effects of
MHT, including estrogen-alone therapy (ET) and estrogen plus progestin therapy (EPT), in
perimenopausal or postmenopausal women in all countries and settings. All health
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outcomes in previous systematic reviews were included, including menopausal symptoms,
surrogate endpoints, biomarkers, various morbidity outcomes, and mortality. Two investiga-
tors independently extracted data and assessed methodological quality of systematic
reviews using the updated 16-item AMSTAR 2 instrument. Random-effects robust variance
estimation was used to combine effect estimates, and 95% prediction intervals (PIs) were
calculated whenever possible. We used the term MHT to encompass ET and EPT, and
results are presented for MHT for each outcome, unless otherwise indicated. Sixty system-
atic reviews were included, involving 102 meta-analyses of RCTs and 38 of observational
studies, with 102 unique outcomes. The overall quality of included systematic reviews was
moderate to poor. In meta-analyses of RCTs, MHT was beneficial for vasomotor symptoms
(frequency: 9 trials, 1,104 women, risk ratio [RR] 0.43, 95% CI 0.33 to 0.57, p < 0.001; sever-
ity: 7 trials, 503 women, RR 0.29, 95% CI 0.17 to 0.50, p = 0.002) and all fracture (30 trials,
43,188 women, RR 0.72, 95% CI 0.62 to 0.84, p = 0.002, 95% PI 0.58 to 0.87), as well as
vaginal atrophy (intravaginal ET), sexual function, vertebral and nonvertebral fracture, dia-
betes mellitus, cardiovascular mortality (ET), and colorectal cancer (EPT), but harmful for
stroke (17 trials, 37,272 women, RR 1.17, 95% CI 1.05 to 1.29, p = 0.027) and venous
thromboembolism (23 trials, 42,292 women, RR 1.60, 95% CI 0.99 to 2.58, p = 0.052, 95%
PI 1.03 to 2.99), as well as cardiovascular disease incidence and recurrence, cerebrovascu-
lar disease, nonfatal stroke, deep vein thrombosis, gallbladder disease requiring surgery,
and lung cancer mortality (EPT). In meta-analyses of observational studies, MHT was asso-
ciated with decreased risks of cataract, glioma, and esophageal, gastric, and colorectal can-
cer, but increased risks of pulmonary embolism, cholelithiasis, asthma, meningioma, and
thyroid, breast, and ovarian cancer. ET and EPT had opposite effects for endometrial can-
cer, endometrial hyperplasia, and Alzheimer disease. The major limitations include the
inability to address the varying effects of MHT by type, dose, formulation, duration of use,
route of administration, and age of initiation and to take into account the quality of individual
studies included in the systematic reviews. The study protocol is publicly available on
PROSPERO (CRD42017083412).
Conclusions
MHT has a complex balance of benefits and harms on multiple health outcomes. Some
effects differ qualitatively between ET and EPT. The quality of available evidence is only
moderate to poor.
Author summary
Why was this study done?
• By 2050, it is estimated that worldwide more than 1.6 billion women will have reached
menopause or be postmenopausal, up from 1 billion in 2020.
• Up to 75% of menopausal women are affected by bothersome menopausal symptoms,
such as hot flashes and night sweats.
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• Menopausal hormone therapy (MHT) is the most effective treatment for alleviating
menopausal symptoms, but its effects on numerous health outcomes remain uncertain.
What did the researchers do and find?
• We included 60 published systematic reviews of MHT use in menopausal women,
involving 102 meta-analyses of randomized controlled trials and 38 of observational
studies, and synthesized the evidence on 102 health outcomes.
• Overall, MHT had a complex balance of benefits and harms; for example, beyond allevi-
ation of menopausal symptoms, it was associated with decreased risks of bone fracture,
diabetes mellitus, and esophageal, gastric, and colorectal cancer, but increased risks of
stroke, venous thromboembolism, gallbladder disease, and breast and ovarian cancer.
• The available clinical data in support of MHT reducing the risk of coronary heart dis-
ease and all-cause mortality in women aged<60 years or within 10 years from meno-
pause (known as the “timing hypothesis”) were only suggestive.
• The overall quality of included systematic reviews was moderate to poor.
What do these findings mean?
• This overview of the evidence landscape could help guideline developers and decision-
makers better appreciate the trade-offs between the benefits and harms associated with
MHT use in menopausal women.
• More data are needed to evaluate the timing hypothesis for coronary heart disease and
all-cause mortality.
• Clinicians should evaluate the scientific strength of systematic reviews prior to consider-
ing applying their results in clinical practice.
Introduction
Longevity is increasing worldwide for women. By 2050, the world’s women aged 50 years and
older are projected to total 1.6 billion, up from 1 billion in 2020 [1]. Natural menopause occurs
at a mean age of 49 years [2]. Vasomotor symptoms, including hot flashes and night sweats,
are the hallmark symptoms of menopause, affecting approximately 75% of perimenopausal
women, and may persist for a decade or longer [3]. In addition, up to 84% of postmenopausal
women experience genitourinary symptoms, such as vulvovaginal atrophy and incontinence
[4]. The burden of menopausal symptoms can considerably affect the personal, social, and
work lives of women [3]. Menopausal hormone therapy (MHT) is the most effective treatment
for managing vasomotor and genitourinary symptoms [5,6]. In high-income countries, there
were about 600 million woman-years of MHT use in the period 1970–2019, and about 12 mil-
lion users in the 2010s, of whom 6 million users were in the US and UK alone [7,8].
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For several decades, the possible health effects of MHT, beyond alleviation of menopausal
symptoms, have been debated. Nevertheless, a systematic, comprehensive assessment in this
regard is lacking. More recently, leading medical societies provided clinical practice guidelines
for the use of MHT in women [5,6,9–11]. The guidelines lacked consistency regarding some
outcomes, such as coronary heart disease (CHD) and all-cause mortality [5,6,9–11]. Often,
these guidelines incorporated systematic reviews and meta-analyses as key evidence support
for the recommendations, but with little attention to their quality or scientific validity [5,9].
Numerous empirical evaluations have found that poor quality and major flaws impede many
published systematic reviews in diverse disciplines [12–18]. In light of the uncertainty sur-
rounding the effects of MHT on numerous health outcomes in women, it is important that the
quality of systematic reviews contributing to current guidelines and recommendations be criti-
cally appraised in order to provide the highest level and most reliable basis for recommenda-
tions in clinical practice. Consequently, we performed an outcome-wide umbrella review to
summarize the evidence across existing systematic reviews and meta-analyses on the effects of
MHT in perimenopausal and postmenopausal women [19]. We sought to provide a compre-
hensive overview of the benefits and harms of MHT use, evaluate the validity of effects
reported across systematic reviews, assess potential biases in the literature, and examine the
credibility of the methods of existing systematic reviews.
Methods
An umbrella review is a review of published systematic reviews, with or without meta-analyses,
related to a given topic or question [20–22]. It systematically integrates evidence from multiple
systematic reviews to present a comprehensive view of the evidence landscape, readily provid-
ing guideline developers and decision-makers with the currently available highest level of evi-
dence relevant to the question posed [21,22]. The protocol for the current umbrella review was
registered in the International Prospective Register of Systematic Reviews (PROSPERO)
(CRD42017083412). This study was reported as per the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) guideline [23] (S1 PRISMA Checklist). Ethical
approval was not required for this study.
Literature search and eligibility criteria
We searched MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, Database of
Abstracts of Reviews of Effects, ISI Web of Science, CINAHL, Google Scholar, Allied and
Complementary Medicine Database, Global Health, PsycINFO, CAB International, and WHO
Global Health Library from inception to November 26, 2017. No language restriction was
applied. Table A in S1 Text presents the detailed search strategies for each electronic database.
Two investigators independently screened the titles and/or abstracts and reviewed full-text
articles for eligibility. Any discrepancies were resolved by discussion. References of the
included articles were also manually checked to identify additional eligible articles.
Articles were selected for inclusion if they met the following Population, Intervention or
Exposure, Comparator, Outcome, Study design (PI[E]COS) criteria: (1) population: perimen-
opausal or postmenopausal women of any ethnicity in any country or setting; (2) intervention
or exposure: any type of MHT, including estrogen-alone therapy (ET) and estrogen plus pro-
gestin therapy (EPT), at any dose, duration, and route of administration; (3) comparator: pla-
cebo or no treatment; (4) outcome: any health outcome or indicator, including menopausal
symptoms; and (5) study design: systematic review, with or without meta-analysis, of random-
ized controlled trials (RCTs) or observational epidemiological studies (cohort and case–con-
trol design). We excluded reviews without a systematic search, systematic reviews that
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examined the effects of progestin or selective estrogen receptor modulators (e.g., raloxifene),
systematic reviews that compared different types of MHT, and individual participant meta-
analyses. If more than 1 systematic review existed on the same scientific question (those with
the same PI[E]COS elements), we included the most recent and largest review. In some cases
where the largest meta-analysis was not the most recent, we retained the largest and updated it
by including the nonoverlapping studies from the most recent review. If the same outcome
was investigated in systematic reviews of RCTs and of observational studies or in systematic
reviews with different population or intervention/exposure characteristics, all reviews were
included for that outcome in order to get a complete picture of the benefits or harms associ-
ated with MHT. We categorized outcomes according to the International Classification of Dis-
eases–11th Revision (ICD-11) [24]. We performed an updated search on December 17, 2020,
for studies published since November 26, 2017, but the literature obtained did not change the
conclusions reached based on the originally included studies. A summary of the literature
obtained from the updated search is given in S2 Text.
Data extraction and quality assessment
Two investigators independently extracted data by outcome using a customized data extrac-
tion form. For each systematic review, we extracted title of the review, citation details (e.g.,
author list, journal, year of publication), country, PI(E)COS elements, number of included
studies, and meta-analysis method (where applicable). For each individual study included in
each meta-analysis, we extracted first author, year of publication, country, study design, phase
of prevention, age of participants, menopausal status, type of MHT, route of administration,
length of follow-up (where applicable), outcome examined, number of events for binary out-
comes or means and standard deviations for continuous outcomes and total number of partici-
pants in intervention and control groups in RCTs, number of cases and controls in case–
control studies or total population in cohort studies, type of effect estimate (mean difference,
standardized mean difference, risk ratio [RR], odds ratio, incidence rate ratio, or hazard ratio),
and effect estimate with 95% confidence interval (CI). For systematic reviews without meta-
analysis, we abstracted only key findings or conclusions.
Given the issues (e.g., incomplete data, poor data quality) in a sample of included meta-
analyses [25–28] as well as the high prevalence of data extraction errors from empirical evalua-
tions [29], we devoted extensive efforts to obtaining and validating the data for the individual
studies in each meta-analysis. We developed 2 separate protocols for extracting data from
included systematic reviews of RCTs and of observational studies based on the assessment of 5
included reviews [25–28,30] (Figs A and B in S1 Text). In brief, for meta-analyses of RCTs that
provided insufficient or inadequate data for individual studies, the full texts of these studies
were retrieved, from which data were extracted. In addition, outcome data from the Women’s
Health Initiative (WHI) trials were updated based on the most recent publications [31–34].
For meta-analyses of observational studies, we extracted all data from individual studies
regardless of the availability of data in the meta-analyses, and then compared these data with
the data in the meta-analyses. We verified the inclusion of individual studies in each meta-
analysis by checking the eligibility of each study against the PI(E)COS criteria of the meta-
analysis, and studies were further excluded if found not to meet the criteria. In a few cases
(e.g., no references provided), the review authors were contacted to request additional
information.
Two investigators independently assessed the methodological quality of included systematic
reviews using the updated 16-item AMSTAR 2 (A MeaSurement Tool to Assess systematic
Reviews) instrument [35]. Quality appraisal of individual studies is beyond the scope of an
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umbrella review. Any discrepancies during data extraction and quality assessment were
resolved by discussion or arbitration by a third investigator.
Data synthesis and analysis
We developed a priori an analysis protocol including justification of the statistical methods
applied to this umbrella review (S3 Text). In brief, for each meta-analysis we calculated the
summary average effect and its 95% CI using the random-effects robust variance estimation
method [36]. We quantified the extent of heterogeneity by estimating the between-study stan-
dard deviation [37,38]. To further account for heterogeneity, we estimated the predictive dis-
tribution for the true effect in a new study [39–42]. The 95% prediction interval (PI) estimates
the middle 95% area of the predictive distribution, reflecting the variation in the true effects
across study settings, and predicts with 95% confidence the true effect in a new study that is
similar to the studies in the meta-analysis [40,43]. Based on simulation results [40,42], the 95%
PI was calculated only in meta-analyses of�10 studies. Next, we examined small-study effects
with a random-effects Egger regression [44,45], which assesses whether there is an association
between treatment effect size and its standard error. To assess publication bias, we used the
Vevea and Hedges selection model [46] and the S-value [47], which represents the severity of
publication bias that would hypothetically be required to shift the point estimate to the null.
Lastly, for meta-analyses of observational studies, we assessed the robustness of meta-analysis
results to potential residual confounding using the E-value [48,49] and its equivalents for
meta-analyses [42,50].
The primary analyses focused on the average effects of any type of hormone therapy (ET or
EPT). A subgroup analysis by MHT type was conducted to assess whether the effect varied
qualitatively between ET and EPT. A qualitative difference means that the effects of ET and
EPT do not point in the same direction [51,52]. We use the term MHT to encompass ET and
EPT, and results are presented for MHT, unless a qualitative difference was indicated between
ET and EPT, in which case results are presented separately for them. We grouped the data
according to whether the intervention or exposure was primary or secondary prevention. We
defined primary prevention as reducing the risk of occurrence of a disease among individuals
who do not have that disease at the beginning of follow-up, and secondary prevention as
reducing the severity or progression of a disease among individuals who already have that dis-
ease or the risk of recurrence among individuals who have a history of that disease. The analy-
ses were conducted separately for RCTs and observational studies. For observational studies,
the analyses were stratified by recency of MHT use (ever, current, or past). Finally, based on
the amount and the consistency of the body of evidence, we graded the evidence from meta-
analyses as consistent, highly suggestive, suggestive, controversial, or insufficient, following
the criteria described in Tables 1 and 2. All estimates were converted to the RR scale [48,53–
55], and results are presented on that scale, except where otherwise noted. All statistical analy-
ses were performed using R software (version 4.0.1) [56]. The R scripts are available in S4 and
S5 Texts, and the datasets are available at Open Science Framework (https://osf.io/dsy37/).
Results
Characteristics of included studies
In total, we identified 10,550 records, scrutinized 160 full-text articles, and ultimately included
60 articles (29 systematic reviews of RCTs [25,26,30,57–82], 27 of observational studies
[27,28,83–107], and 4 of both RCTs and observational studies [108–111]) (Fig 1). The studies
were published between 1995 and 2017. The 33 systematic reviews of RCTs reported 102
meta-analyses (1 systematic review without meta-analysis), with 81 unique outcomes; the 31
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systematic reviews of observational studies reported 38 meta-analyses (2 systematic reviews
without meta-analysis), with 40 unique outcomes; 19 outcomes overlapped between meta-
analyses of RCTs and of observational studies, and thus in total 102 unique outcomes were
reported across all included systematic reviews. Characteristics of the included systematic
reviews for each outcome are summarized in Tables B and C in S1 Text.
Table 1. Summary of evidence grading for meta-analyses of randomized controlled trials on menopausal hormone therapy and incidence of diseases and other
health outcomes.
Evidence Criteria Meta-analyses of randomized controlled trialsa
Outcomes with beneficial effects Outcomes with harmful effects
Consistent 95% CI of the mean effect excludes null value
with no heterogeneity, or predictive
distributionb contains an extreme proportion
(>90%) of true effects in the direction of the
mean effect
All fracture, vertebral fracture, nonvertebral
fracture, colorectal cancer (EPT),
cardiovascular mortality (ET)
Cardiovascular disease, cerebrovascular disease,
stroke, nonfatal stroke, venous thromboembolism,
deep vein thrombosis, gallbladder disease
requiring surgery, endometrial hyperplasia (ET),
lung cancer mortality (EPT)
Highly
suggestive
95% CI of the mean effect excludes null value,
with heterogeneity present but predictive
distribution not estimablec, or predictive
distribution contains a substantial proportion
(70%–90%) of true effects in the direction of the
mean effect
Vasomotor symptomsd, vasomotor symptom
severityd, vaginal atrophy (intravaginal ET)d,
sexual function, urinary incontinenced,
diabetes mellitus
Cardiovascular disease recurrence
Suggestive 95% CI of the mean effect includes null value,
predictive distribution not estimablec, and 95%
CI of the most precise studye excludes null value
Breast cancer (ET), endometrial cancer (EPT),
hip fracture (EPT), sleep quality (EPT),
skeletal muscle strength (EPT), recurrent
urinary tract infection (ET)d
Breast cancer (EPT), dementia (EPT), pulmonary
embolism (EPT), irregular vaginal bleeding (ET)
Controversial Predictive distribution contains a non-negligible
proportion (>30%) of true effects in both the
same and the opposite direction of the mean
effect
None None
Insufficient Insufficient evidence to draw conclusions All-cause mortality, all cancer incidence and mortality, lung cancer incidence and mortality (ET),
breast cancer recurrence and mortality, ovarian cancer incidence and overall survival, endometrial
cancer (ET), colorectal cancer incidence (ET) and mortality, cardiovascular mortality (EPT),
cerebrovascular disease recurrence, stroke recurrence, fatal stroke incidence and recurrence,
nonfatal stroke recurrence, transient ischemic attack incidence and recurrence, coronary heart
disease incidence and recurrence and mortality, myocardial infarction incidence and recurrence,
fatal and nonfatal myocardial infarction incidence and recurrence, angina pectoris incidence and
recurrence, cardiac death, coronary revascularization, venous thromboembolism recurrence, deep
vein thrombosis recurrence, pulmonary embolism incidence (ET) and recurrence, dementia (ET),
Alzheimer disease, cognitive function (in healthy women and in women with dementia), hip
fracture (ET), endometrial hyperplasia (EPT), irregular vaginal bleeding (EPT), sleep quality (ET),
occurrence and recurrence of depressive symptoms
Small-study effects existed for all fracture, sexual function, urinary incontinence, and deep vein thrombosis; the Egger regression test was used to examine whether
smaller studies tended to show more pronounced effects than larger studies; it was applied only in meta-analyses of�10 studies; more information is available in S3
Text. Meta-analysis results were robust to severe or extreme publication bias for all fracture, vasomotor symptoms, stroke, nonfatal stroke, venous thromboembolism,
gallbladder disease requiring surgery, and endometrial hyperplasia (ET); “robust to severe or extreme publication bias” means that the meta-analysis results cannot be
explained away by hypothetical publication bias that greatly exceeds empirical estimates of publication bias severity in medicine (i.e., hypothetical publication bias in
which statistically significant positive effects are 4-fold more likely to be published and meta-analyzed than nonsignificant or negative effects); more information is
available in S3 Text. CI, confidence interval; EPT, estrogen plus progestin therapy; ET, estrogen-alone therapy.
aThe average effects of any menopausal hormone therapy (ET or EPT) in perimenopausal or postmenopausal women. When subgroup analysis by type of hormone
therapy indicated a qualitative difference or statistically significant results were found for only 1 type of hormone therapy, results are presented separately for them. The
effects refer to outcome incidence, unless otherwise indicated.
bThe predictive distribution describes how the true effect sizes across studies are distributed around the summary average effect. Predictive distribution was estimated
only in meta-analyses of�10 studies. More information is available in S3 Text.
cDue to a small number of studies (<10) being included in the meta-analysis.
dIn women who already have the outcome of interest.
eThe study with the smallest standard error in each meta-analysis.
https://doi.org/10.1371/journal.pmed.1003731.t001
PLOS MEDICINE Menopausal hormone therapy and women’s health
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003731 August 2, 2021 7 / 27
Quality assessment of included studies
For the 7 AMSTAR 2 critical domains, 36% of the included systematic reviews established a
priori a protocol for the review, 59% performed a comprehensive literature search, 34% pro-
vided a list of excluded studies with justification, 78% used a satisfactory technique for assess-
ing the risk of bias in individual studies, 47% used the random-effects model for meta-analysis,
47% discussed the impact of risk of bias in individual studies in the interpretation of the results
of the review, and 29% performed graphical or statistical tests for publication bias and dis-
cussed the likelihood and magnitude of impact of publication bias. Fig 2 presents a summary
Table 2. Summary of evidence grading for meta-analyses of observational epidemiological studies on menopausal hormone therapy and incidence of diseases and
other health outcomes.
Evidence Criteria Meta-analyses of observational epidemiological studiesa
Outcomes with beneficial effects Outcomes with harmful effects
Consistent 95% CI of the mean effect excludes null value
with no heterogeneity, or predictive
distributionb contains an extreme proportion
(>90%) of true effects in the direction of the
mean effect
Esophageal cancer, gastric cancer, colorectal
cancer, breast-cancer-specific survivalc, breast
cancer overall survivalc, ovarian cancer overall
survivald, Alzheimer disease (ET), cataract,
coronary heart disease, all-cause mortality
Breast cancer (EPT), endometrial cancer (ET),
Alzheimer disease (EPT), venous
thromboembolism, deep vein thrombosis,
pulmonary embolism, cholelithiasis, asthma
Highly
suggestive
95% CI of the mean effect excludes null value,
with heterogeneity present but predictive
distribution not estimablee, or predictive
distribution contains a substantial proportion
(70%–90%) of true effects in the direction of
the mean effect
Glioma Breast cancer (ET), ovarian cancer, meningioma,
thyroid cancer
Suggestive 95% CI of the mean effect includes null value,
predictive distribution not estimablee, and 95%
CI of the most precise studyf excludes null
value
Breast cancer recurrenced, lung cancer overall
survivalg, diabetes mellitus, coronary heart
disease mortality, cardiovascular disease
incidence and mortality
Cutaneous melanoma (ET), endometrial cancer
(EPT), systemic lupus erythematosus, Parkinson
disease
Controversial Predictive distribution contains a non-
negligible proportion (>30%) of true effects in
both the same and the opposite direction of the
mean effect
Breast cancer mortality, pancreatic cancer, lung cancer
Insufficient Insufficient evidence to draw conclusions Primary liver cancer, endometrial cancer mortality, ovarian cancer recurrence, head and neck cancer,
cutaneous melanoma (EPT), osteoarthritis, dementia
Small-study effects existed for breast-cancer-specific survival, breast cancer overall survival, and glioma; the Egger regression test was used to examine whether smaller
studies tended to show more pronounced effects than larger studies; it was applied only in meta-analyses of�10 studies; more information is available in S3 Text. Meta-
analysis results were robust to severe or extreme publication bias for esophageal cancer, gastric cancer, colorectal cancer, breast cancer (EPT), breast cancer (ET), breast-
cancer-specific survival, breast cancer overall survival, endometrial cancer (ET), ovarian cancer incidence and overall survival, coronary heart disease, venous
thromboembolism, asthma, and cholelithiasis; “robust to severe or extreme publication bias” means that the meta-analysis results cannot be explained away by
hypothetical publication bias that greatly exceeds empirical estimates of publication bias severity in medicine (i.e., hypothetical publication bias in which statistically
significant positive effects are 4-fold more likely to be published and meta-analyzed than nonsignificant or negative effects); more information is available in S3 Text. CI,
confidence interval; EPT, estrogen plus progestin therapy; ET, estrogen-alone therapy.
aThe average effects of any menopausal hormone therapy (ET or EPT) in perimenopausal or postmenopausal women. When subgroup analysis by type of hormone
therapy indicated a qualitative difference or statistically significant results were found for only 1 type of hormone therapy, results are presented separately for them. The
effects refer to outcome incidence, unless otherwise indicated.
bThe predictive distribution describes how the true effect sizes across studies are distributed around the summary average effect. Predictive distribution was estimated
only in meta-analyses of�10 studies. More information is available in S3 Text.
cUse of menopausal hormone therapy before or after diagnosis of cancer.
dUse of menopausal hormone therapy after diagnosis of cancer.
eDue to a small number of studies (<10) being included in the meta-analysis.
fThe study with the smallest standard error in each meta-analysis.
gUse of menopausal hormone therapy before diagnosis of cancer.
https://doi.org/10.1371/journal.pmed.1003731.t002
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of quality assessment by outcome across all included systematic reviews. Each AMSTAR 2
domain judgment for each outcome is available in Tables D and E in S1 Text.
Benefits and harms of MHT
In total, we included 936 individual study estimates from RCTs and 380 from observational
studies (190 from case–control and 190 from cohort studies) for meta-analysis. The median
number of study estimates per outcome in meta-analyses of RCTs and of observational studies
was 5 (range 1–55) and 7 (range 1–71), respectively. Tables 1 and 2 summarize the evidence
for all disease outcomes (both primary and secondary prevention) from meta-analyses of
RCTs and of observational studies, respectively. The surrogate outcomes with consistent or
highly suggestive evidence from meta-analyses of RCTs are summarized in Fig C in S1 Text.
Fig 1. Flow chart for study selection process. MHT, menopausal hormone therapy; OE, observational
epidemiological study; RCT, randomized controlled trial.
https://doi.org/10.1371/journal.pmed.1003731.g001
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Consistent or highly suggestive evidence means that the 95% CI of the summary average effect
excludes the null or the estimated predictive distribution contains a substantial proportion
(�70%) of true effects in the direction of the average effect (Tables 1 and 2). More detailed
results are available in Tables F to X in S1 Text. Below we described the meta-analysis results
for only outcomes with consistent or highly suggestive evidence (Figs 3 and 4, and Fig C in S1
Text). The meta-analysis results for other evidence levels, as well as small-study effects, publi-
cation bias, and sensitivity analysis for residual confounding in observational studies, are
described in S1 Text.
Fig 2. Quality assessment by outcome presented as percentages across all included systematic reviews. PI(E)CO, Population, Intervention or Exposure, Comparator,
Outcome; RoB, risk of bias.
https://doi.org/10.1371/journal.pmed.1003731.g002
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Neoplasms. In RCTs, EPT was associated with a decreased risk of colorectal cancer (5 tri-
als, 24,624 women, RR 0.79, 95% CI 0.64 to 0.98, p = 0.045), but an increased risk of lung can-
cer mortality (3 trials, 19,513 women, RR 1.10, 95% CI 1.00 to 1.21, p = 0.047). In
observational studies, MHT was associated with decreased risks of glioma (10 studies,
1,580,830 women, RR 0.87, 95% CI 0.72 to 1.04, p = 0.11, 95% PI 0.57 to 1.21), esophageal can-
cer (5 studies, 203,548 women, RR 0.70, 95% CI 0.60 to 0.81, p = 0.009), gastric cancer (6 stud-
ies, 616,630 women, RR 0.78, 95% CI 0.70 to 0.86, p = 0.003), and colorectal cancer (25 studies,
527,776 women, RR 0.83, 95% CI 0.77 to 0.89, p< 0.001, 95% PI 0.57 to 1.06). Among women
with a history of breast cancer, both pre- and post-diagnosis MHT use was associated with
improved breast-cancer-specific survival (11 studies, 24,753 women, RR 0.72, 95% CI 0.59 to
0.88, p = 0.006, 95% PI 0.48 to 0.93) and breast cancer overall survival (16 studies, 39,593
women, RR 0.82, 95% CI 0.75 to 0.89, p< 0.001, 95% PI 0.59 to 1.06), and among women with
a history of ovarian cancer, post-diagnosis MHT use was associated with improved ovarian
cancer overall survival (3 studies, 599 women, RR 0.81, 95% CI 0.71 to 0.91, p = 0.025). On the
Fig 3. Consistent or highly suggestive evidence from meta-analyses of randomized controlled trials on menopausal hormone therapy and
incidence of diseases and other health outcomes. The average effects of any menopausal hormone therapy (ET or EPT) in perimenopausal or
postmenopausal women, unless otherwise stated. All estimates are from our own analysis apart from diabetes mellitus. Subgroup analysis results
by type of menopausal hormone therapy can be found in Tables F to K in S1 Text. The center of each square represents the summary average
effect for each outcome, and the horizontal line represents the corresponding 95% CI. CI, confidence interval; EPT, estrogen plus progestin
therapy; ET, estrogen-alone therapy; NA, not available or not applicable. aIn women who already have the outcome of interest. bThe effect
measures for continuous outcomes were converted into the risk ratio scale for comparison; the results in original scale can be found in Tables F
and I in S1 Text.
https://doi.org/10.1371/journal.pmed.1003731.g003
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other hand, MHT was associated with increased risks of meningioma (13 studies, 1,479,871
women, RR 1.14, 95% CI 0.98 to 1.33, p = 0.076, 95% PI 0.61 to 1.59), thyroid cancer (12 stud-
ies, 802,681 women, RR 1.09, 95% CI 0.88 to 1.34, p = 0.36, 95% PI 0.82 to 1.44), ovarian cancer
(37 studies, 2,389,636 women, RR 1.16, 95% CI 1.06 to 1.26, p = 0.002, 95% PI 0.71 to 1.54),
and breast cancer (71 studies, 3,331,883 women, RR 1.25, 95% CI 1.19 to 1.31, p< 0.001, 95%
PI 0.93 to 1.74; Table L in S1 Text). No qualitative difference in breast cancer risk between ET
and EPT was found (Fig 4). In women with a uterus, ET was associated with an increased risk
Fig 4. Consistent or highly suggestive evidence from meta-analyses of observational epidemiological studies on menopausal hormone therapy and incidence of
diseases and other health outcomes. The average effects of any menopausal hormone therapy (ET or EPT) in perimenopausal or postmenopausal women, unless
otherwise stated. The estimates are for ever use of menopausal hormone therapy, unless otherwise stated. All estimates are from our own analysis. Subgroup analysis
results by type and recency of menopausal hormone therapy use can be found in Tables L to Q in S1 Text. The center of each square represents the summary average effect
for each outcome, and the horizontal line represents the corresponding 95% CI. Cc, case–control study; CI, confidence interval; Co, cohort study; EPT, estrogen plus
progestin therapy; ET, estrogen-alone therapy; NA, not available or not applicable. aCurrent use of menopausal hormone therapy. bUse of menopausal hormone therapy
before or after diagnosis of cancer. cUse of menopausal hormone therapy after diagnosis of cancer.
https://doi.org/10.1371/journal.pmed.1003731.g004
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of endometrial cancer (18 studies, 836,988 women, RR 2.55, 95% CI 2.05 to 3.18, p< 0.001,
95% PI 1.01 to 6.99).
Diseases of the circulatory system. In RCTs, MHT was associated with increased risks of
venous thromboembolism (23 trials, 42,292 women, RR 1.60, 95% CI 0.99 to 2.58, p = 0.052,
95% PI 1.03 to 2.99) and deep vein thrombosis (14 trials, 38,923 women, RR 1.39, 95% CI 0.68
to 2.84, p = 0.19, 95% PI 1.01 to 2.38). No evidence of effect was found with regard to CHD
incidence (17 trials, 39,448 women, RR 1.02, 95% CI 0.82 to 1.26, p = 0.75; Table F in S1 Text)
and recurrence (8 trials, 5,045 women, RR 0.97, 95% CI 0.76 to 1.24, p = 0.65; Table I in S1
Text). In observational studies, MHT was associated with a decreased risk of CHD (10 studies,
91,067 women, RR 0.82, 95% CI 0.69 to 0.96, p = 0.021, 95% PI 0.69 to 1.14), but increased
risks of venous thromboembolism (4 studies, 123,376 women, RR 1.99, 95% CI 1.53 to 2.58,
p = 0.006), deep vein thrombosis (3 studies, 11,055 women, RR 2.26, 95% CI 1.14 to 4.49,
p = 0.038), and pulmonary embolism (3 studies, 122,745 women, RR 2.05, 95% CI 1.49 to 2.83,
p = 0.017).
Genitourinary system. In RCTs, MHT was associated with improved vasomotor symp-
toms (frequency: 9 trials, 1,104 women, RR 0.43, 95% CI 0.33 to 0.57, p< 0.001; severity: 7 tri-
als, 503 women, RR 0.29, 95% CI 0.17 to 0.50, p = 0.002) and urinary incontinence (13 trials,
16,999 women, RR 0.82, 95% CI 0.62 to 1.09, p = 0.15, 95% PI 0.36 to 1.94). Intravaginal ET
was associated with improved vaginal atrophy (5 trials, 1,903 women, RR 0.31, 95% CI 0.12 to
0.81, p = 0.03). On the other hand, oral ET was associated with an increased risk of endome-
trial hyperplasia (13 trials, 3,884 women, RR 6.93, 95% CI 2.07 to 23.23, p = 0.007, 95% PI 1.18
to 50.68).
Functioning assessment. In RCTs, MHT was associated with improved sexual function
(measured by a composite score of arousal and sexual interest, orgasm, and pain) (10 trials,
2,826 women, RR 0.82, 95% CI 0.71 to 0.96, p = 0.017, 95% PI 0.57 to 1.28).
Bone loss and fracture. In RCTs, MHT was associated with increased bone mineral den-
sity at lumbar spine, forearm, femoral neck, and proximal femur (Fig C in S1 Text), and
decreased risks of all fracture (30 trials, 43,188 women, RR 0.72, 95% CI 0.62 to 0.84, p = 0.002,
95% PI 0.58 to 0.87), vertebral fracture (16 trials, 34,336 women, RR 0.69, 95% CI 0.50 to 0.94,
p = 0.033), and nonvertebral fracture (26 trials, 25,921 women, RR 0.76, 95% CI 0.62 to 0.94,
p = 0.025, 95% PI 0.60 to 1.02).
Diseases of the nervous system. In RCTs, MHT was associated with increased risks of
cerebrovascular disease (21 trials, 42,281 women, RR 1.25, 95% CI 1.04 to 1.50, p = 0.03),
stroke (17 trials, 37,272 women, RR 1.17, 95% CI 1.05 to 1.29, p = 0.027), and nonfatal stroke
(11 trials, 32,656 women, RR 1.35, 95% CI 1.08 to 1.69, p = 0.025). In observational studies, ET
was associated with a decreased risk of Alzheimer disease (10 studies, 8,419 women, RR 0.76,
95% CI 0.60 to 0.96, p = 0.028, 95% PI 0.56 to 1.03), while EPT was associated with an
increased risk (2 studies, 3,186 women, RR 1.42, 95% CI 1.24 to 1.62, p = 0.02).
Diseases of the visual system. In observational studies, MHT was associated with a
decreased risk of cataract (7 studies, 43,082 women, RR 0.87, 95% CI 0.79 to 0.97, p = 0.022).
Diseases of the respiratory system. In observational studies, MHT was associated with
an increased risk of asthma (5 studies, 163,161 women, RR 1.41, 95% CI 1.09 to 1.81,
p = 0.023).
Diseases of the digestive system. In RCTs, MHT was associated with an increased risk of
gallbladder disease requiring surgery (5 trials, 26,526 women, RR 1.63, 95% CI 1.31 to 2.04,
p = 0.011). In observational studies, MHT was associated with an increased risk of cholelithia-
sis (8 studies, 277,380 women, RR 1.63, 95% CI 1.41 to 1.88, p< 0.001).
Endocrine, nutritional, and metabolic diseases. In RCTs, MHT was associated with
lower levels of fasting glucose and fasting insulin and reduced insulin resistance in women
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with and without diabetes mellitus (Fig C in S1 Text), and a decreased risk of developing dia-
betes mellitus (RR 0.70, 95% CI 0.60 to 0.90; Table X in S1 Text). In addition, MHT was associ-
ated with lower levels of low-density lipoprotein cholesterol (LDL-C), lipoprotein(a), and
plasminogen activator inhibitor-1 (PAI-1), but higher levels of triglycerides and C-reactive
protein (Fig C in S1 Text).
Other diseases not elsewhere classified. In RCTs, MHT was associated with increased
risks of cardiovascular disease incidence (22 trials, 39,080 women, RR 1.29, 95% CI 0.99 to
1.68, p = 0.056, 95% PI 1.02 to 1.61) and recurrence (11 trials, 5,922 women, RR 1.08, 95% CI
0.94 to 1.25, p = 0.18, 95% PI 0.94 to 1.27), while ET was associated with a small reduction in
cardiovascular mortality (3 trials, 11,081 women, RR 0.97, 95% CI 0.95 to 0.99, p = 0.039). In
observational studies, MHT was associated with a decreased risk of all-cause mortality (6 stud-
ies, 106,642 women, RR 0.89, 95% CI 0.82 to 0.97, p = 0.029), but no evidence of effect was
found in RCTs (38 trials, 47,757 women, RR 0.99, 95% CI 0.83 to 1.18, p = 0.72; Table F in S1
Text).
Discussion
Summary of key findings
In this umbrella review, consistent or highly suggestive evidence from RCTs found that MHT
was beneficial for vasomotor symptoms, vaginal atrophy (intravaginal ET), sexual function, all
fracture, vertebral and nonvertebral fracture, diabetes mellitus, cardiovascular mortality (ET),
and colorectal cancer (EPT), but harmful for cardiovascular disease incidence and recurrence,
cerebrovascular disease, stroke, nonfatal stroke, venous thromboembolism, deep vein throm-
bosis, gallbladder disease requiring surgery, and lung cancer mortality (EPT). Consistent or
highly suggestive evidence from observational studies found that MHT was associated with
decreased risks of cataract, glioma, and esophageal, gastric, and colorectal cancer, but
increased risks of venous thromboembolism, deep vein thrombosis, pulmonary embolism,
cholelithiasis, asthma, meningioma, and thyroid, breast, and ovarian cancer. The effects of ET
and EPT differed qualitatively for endometrial cancer, endometrial hyperplasia, and Alzheimer
disease. The evidence levels for the other disease outcomes ranged from suggestive to
insufficient.
Limitations
Certain limitations need to be taken into account in the interpretation of our findings. First,
umbrella reviews focus on existing systematic reviews, and therefore outcomes not assessed in
a systematic review cannot be included. Second, the studies identified in the updated search in
2020 were not included in the umbrella review. This evidence analysis will be taken into
account in the future when the current umbrella review is updated. Third, we were unable to
take into account the quality of the individual studies included in the systematic reviews. Qual-
ity appraisal of individual studies is not the focus of umbrella reviews, as included systematic
reviews are expected to perform this task. However, as discussed later, included systematic
reviews are generally limited in their usefulness for accurate rating of quality of evidence.
Fourth, it can be expected that the effects of MHT may vary between participants (e.g., based
on age or time since menopause) and treatments (MHT type, dose, formulation, duration of
use, and route of administration). Due to data unavailability, however, we were unable to
address varying effects based on these prognostic factors, particularly for the commonly used
MHT formulations (e.g., estradiol and micronized progesterone). Instead, we used the predic-
tive distribution (e.g., 95% PI) to estimate the range of effects across study settings [40–42].
Thus, the random-effects average effect should be interpreted in conjunction with the
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predictive distribution and the effect from the subset of studies most relevant to the patients
needed to treat [112,113]. Further systematic reviews or umbrella reviews of comparative evi-
dence (e.g., head-to-head randomized trials) on different prognostic factors are warranted.
Breast and ovarian cancer
In observational studies, we found that both ET and EPT were associated with increased inci-
dence of breast and ovarian cancer. Our findings are consistent with those of 2 recent individ-
ual participant meta-analyses of the worldwide epidemiological evidence [7,8]. However,
among women with a history of breast or ovarian cancer, pre- or post-diagnosis MHT use was
associated with improved cancer-specific or overall survival. The findings were further repli-
cated by 2 recent prospective cohort studies [114,115]. One possible explanation for these find-
ings could be that women who used MHT after diagnosis were likely to have used MHT before
diagnosis. Therefore, despite increased incidence of breast and ovarian cancer with MHT use,
MHT users with established breast and ovarian tumors may have better prognosis than nonus-
ers [114,115]. Observational data on MHT and breast cancer mortality were controversial.
Subgroup analysis by MHT type did not account for the divergent results. Data from the Mil-
lion Women Study recently showed that both ET and EPT were associated with increased
breast cancer mortality [116]. It is therefore difficult to interpret the discrepancy in these
results, but one speculation could be that any causal effect of MHT on breast cancer survival
may reasonably result in such divergent results, since mortality reflects the net effects of MHT
on both incidence and survival [117]. Nevertheless, it is unclear whether the inverse associa-
tion between MHT and breast cancer survival is causal or due to residual confounding or
other biases. In our analysis, small-study effects were also present. Furthermore, the HABITS
(Hormonal Replacement Therapy after Breast Cancer—Is It Safe?) trial [118,119], which com-
pared MHT for menopausal symptoms with symptomatic treatment without MHT among
women with a history of breast cancer, found an increased risk of breast cancer recurrence fol-
lowing MHT. The HABITS trial was therefore terminated early [118], along with the Stock-
holm trial [120,121], in which, however, no evidence of increased breast cancer recurrence
with MHT was found. Current guidelines [5,11,122] suggest that, in women with a history of
breast cancer, systemic MHT is generally not recommended for alleviating vasomotor symp-
toms, and low-dose vaginal ET may be an option to manage genitourinary symptoms after
nonhormonal therapies or complementary options have been unsuccessful and after a detailed
discussion of risks and benefits and review with an oncologist. In all, given the paucity of data
from RCTs and the potential biases in the observational evidence, further well-designed longi-
tudinal studies of MHT use in women with a history of breast or ovarian cancer across differ-
ent settings, while controlling for different sources of bias, are warranted to assess causality.
In the WHI trials, a qualitative difference was found in the effects of ET and EPT on breast
cancer incidence, with ET decreasing but EPT increasing the risk [31]. ET was also found to be
associated with lower breast cancer mortality, whereas no evidence of effect was observed for
EPT [31]. Several explanations were proposed to reconcile the discordance between the WHI
trials and observational studies: older women in the WHI trials, confounding in observational
studies, different biological mechanisms of ET and EPT, or simply the play of chance in the
WHI trials [8,31]. Given the extensive amount of epidemiological evidence, replication of the
findings from the WHI trials should be undertaken.
CHD and all-cause mortality
The effects of MHT on CHD and all-cause mortality have long been debated [90,123–128]. In
our analysis, observational data consistently showed up to 18% lower risk of CHD and up to
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11% lower risk of all-cause mortality with ever use of MHT, while RCTs failed to support the
presence of these beneficial effects. The distinction in populations of women between RCTs
and observational studies—i.e., that observational studies generally included younger women
who started MHT around the time of menopause—has led to the well-known “timing hypoth-
esis” [123,124]. According to this hypothesis, MHT reduces CHD and all-cause mortality only
when initiated close to the onset of menopause, but does not reduce or even increases CHD
and all-cause mortality when initiated many years later [123,124]. Indeed, the age-stratification
analyses from the WHI trials found that MHT reduced CHD and all-cause mortality in
women aged 50–59 years, but increased CHD in older women [33,34]. Four meta-analyses of
RCTs assessed the timing hypothesis by stratifying trials according to mean time since meno-
pause or mean age of participants at baseline, showing a highly significant reduction in CHD
and all-cause mortality in women aged<60 years or those <10 years from menopause, but not
in older women [60,76,99,129]. The literature reviews widely adopted the WHI trials and the
meta-analyses as part of the evidence supporting the beneficial effects of MHT in the younger
group of women [123–126]. The results were further carried into current guidelines [5,9,11].
However, it is worth noting that all these analyses are by nature post hoc, and such subgroup
results are most appropriately regarded as hypothesis generation rather than hypothesis confir-
mation due to multiple comparisons [10,128,130,131]. Particularly for the meta-analyses,
because of issues of potential confounding and ecological fallacy [132,133], findings of such
study-level analyses have to be interpreted cautiously. On the other hand, we did not find evi-
dence that MHT caused additional events in women (mean baseline age� 60 years) with
established CHD.
ELITE (Early versus Late Intervention Trial with Estradiol) [134], the first trial specifically
designed to test the timing hypothesis, found that oral estradiol reduced the progression of
subclinical atherosclerosis (measured as carotid-artery intima–media thickness) when initiated
within 6 years after menopause, but not when initiated�10 years after menopause. It is
unclear whether this favorable effect on atherosclerosis will translate into a reduction in risk of
CHD [128]. In addition, the Kronos Early Estrogen Prevention Study (KEEPS) [135], a RCT of
MHT in recently menopausal women (within 3 years after menopause), found no evidence of
effect of oral conjugated equine estrogens or transdermal 17β-estradiol on the progression of
carotid-artery intima–media thickness or coronary artery calcium. Mendelian randomization
studies have demonstrated that several plasma biomarkers (e.g., LDL-C) have a causal role in
CHD [136–140]. Among these biomarkers, however, we found that the effects of MHT were
mixed, with MHT reducing LDL-C, lipoprotein(a), and PAI-1, but increasing triglycerides.
Overall, the available clinical data in support of the beneficial effects of MHT on CHD and all-
cause mortality as well as the timing hypothesis are only suggestive. Current guidelines
[5,6,10,11] suggest that for menopausal women with low cardiovascular risk and no contrain-
dications, MHT could be considered for treatment of bothersome vasomotor symptoms and
prevention of bone loss or fracture for those at elevated risk, but not for primary prevention of
cardiovascular diseases. More clinical as well as biological data are needed to confirm or refute
the timing hypothesis.
Urinary incontinence
The WHI trials found that oral ET or EPT increased the risk of urinary incontinence among
continent women [141]. The 2012 Cochrane review [63] included 13 RCTs, comprising 10
small studies and 3 large studies, to assess the efficacy of MHT in treating urinary inconti-
nence. Four small studies used intravaginal ET, while the rest used oral ET or EPT. Based on
post hoc subgroup analysis, the review concluded that intravaginal ET may improve
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incontinence, while oral ET or EPT may worsen incontinence. Though qualitative differences
between different routes of administration are generally not expected [51], this result was nev-
ertheless carried into the guidelines without caveats [5,9]. In our analysis, small-study effects
were very prominent: All 10 small studies, regardless of route of administration, pointed in the
direction of beneficial effects, while the 3 large studies reported harmful effects. Taken
together, current evidence shows that oral MHT increases the risk of urinary incontinence and
worsens incontinence in postmenopausal women. The opposite effects of systemic and local
MHT should be viewed at best as exploratory.
Credibility of meta-analyses
We found major methodological limitations in a substantial proportion of included meta-anal-
yses, some of which warrant further discussion. First, a fixed-effect meta-analysis model,
instead of a random-effects model, was often used, even when heterogeneity was present or
anticipated a priori. The fixed-effect model assumes that all studies in the meta-analysis share
a common true effect size, whereas the random-effects model assumes that there is a distribu-
tion of true effect sizes [142]. By gathering studies from the published literature, the random-
effects assumption is the only plausible match to the underlying effect distribution [142]. Sec-
ond, when a random-effects model was used, the summary effect was often incorrectly inter-
preted as an estimate of a common effect, as under a fixed-effect model. Under the random-
effects model, the summary effect is an estimate of the mean of a distribution of true effects
across studies [112,113,142]. Third, investigators often relied heavily on statistical methods
(e.g., the Egger test) to deal with publication bias. To address publication bias, there is a need
to obtain a representative sample of studies on a topic (e.g., through comprehensive literature
searches). Fourth, the tools used for risk of bias assessment of individual studies were generally
not comprehensive, and risk of bias was often evaluated by study across outcomes rather than
by outcome across studies, which limited the quality of evidence rating in existing meta-
analyses.
In conclusion, MHT has a complex balance of benefits and harms on various health out-
comes. Some effects differ qualitatively between ET and EPT. Decisions regarding the use of
MHT should consider the full range of effects, along with patients’ values and preferences. The
overall quality of existing systematic reviews is moderate to poor. Clinicians should evaluate
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Suggestive evidence from meta-analyses of randomized controlled trials on menopausal hor-
mone therapy and incidence of diseases and other health outcomes. Fig E: Suggestive evidence
from meta-analyses of observational epidemiological studies on menopausal hormone therapy
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Table A: Characteristics of systematic reviews and/or meta-analyses on menopausal hormone
therapy and multiple outcomes, updated on December 17, 2020. Fig A: Flow chart for study
selection process, updated on December 17, 2020.
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(PDF)
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Supervision: Bo Lundbäck, Cecilia Lässer, Hannu Kankaanranta, Bright I. Nwaru.
PLOS MEDICINE Menopausal hormone therapy and women’s health
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003731 August 2, 2021 19 / 27
Validation: Guo-Qiang Zhang, Jin-Liang Chen, Ying Luo, Maya B. Mathur, Panagiotis Ana-
gnostis, Jing Zhang, Bright I. Nwaru.
Visualization: Guo-Qiang Zhang, Maya B. Mathur, Hannu Kankaanranta, Bright I. Nwaru.
Writing – original draft: Guo-Qiang Zhang, Bright I. Nwaru.
Writing – review & editing: Guo-Qiang Zhang, Jin-Liang Chen, Ying Luo, Maya B. Mathur,
Panagiotis Anagnostis, Ulugbek Nurmatov, Madar Talibov, Jing Zhang, Catherine M.
Hawrylowicz, Mary Ann Lumsden, Hilary Critchley, Aziz Sheikh, Bo Lundbäck, Cecilia
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